• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    GENOME EDITING A PINK LOCUS USING ZINC FINGER NUCLEASES. The present invention relates to methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    公开号:BR112012027532A2
    申请号:R112012027532-1
    申请日:2011-04-25
    公开日:2020-10-13
    发明作者:Xiaoxia Cui；Sigma-Aldrich Co. LLC；Gregory Davis；Philip D. Gregory；Michael C. Holmes；Edward J. Weinstein
    申请人:Sangamo Biosciences, Inc.；
    IPC主号:
    专利说明:

    : UBE it undermines the mormicnc | - 18 UT a Na BR 11 2012 027539; Invention Patent Descriptive Report for "EDITION OF GENOME OF A PINK LOCUS USING ZINC FINGER NUCLEASES ".
    CROSS REFERENCE TO RELATED APPLICATIONS This application claims the benefit of provisional application US 61 / 343,287, filed on April 26, 2010, the disclosure of which is incorporated by reference in its entirety. DECLARATION OF RIGHTS TO INVENTIONS MADE UNDER RESEARCH
    SPONSORED BY THE FEDERAL GOVERNMENT | y o Not applicable. Ss TECHNICAL FIELD Cd The present revelation is in the fields of genome engineering, | 'including insertions / interruptions of somatic and hereditary genes, genomic alterations, generation of alleles carrying random mutations and / or insertion of transgenes in a Rosa locus. l BACKGROUND | Rosa gene products are ubiquitously expressed in all | development phases. As such, this locus has been widely used to express endogenous sequences of endogenous or introduced promoters and to create transgenic mice, for example, from embryonic stem cells. See, for example, Strathdee et al. (2006) PLoS ONE, Issue 1, e4; Nyabi et a /. (2009) Nucl. Acids. Res. 37: e55. However, conventional target insertion methods can | require complicated target vector set. Thus, there is still a need for methods of targeted insertion in and / or modification of the gene | Rosa in a targeted way. Site-specific cleavage precisely targeted to genomic loci offers an efficient and / or alternative supplement for conventional homologous recombination. The creation of a double-strand break (DSB) increases the frequency of homologous recombination at the targeted locus more than 1000 times. More simply, inaccurate repair of a site-specific DSB by non-homologous end joint (NHEJ) can also result in disruption of the gene. The creation of
    2/39 two so-called DSBs result in the deletion of large regions arbitrarily. The modular DNA recognition preferences of the zinc finger protein allows for the rational design of site-specific multi-finger DNA binding proteins. The fusion of the domain of TipollFok | restriction enzyme nuclease for site-specific zinc finger proteins allows the creation of site-specific nucleases See, for example, US Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; 20070134796; 20080154; 20080131962; 2008015996 and International Publication WOs 07/014275 and 2008/133938, all describing the use of zinc finger nucleases and which are incorporated in their entirety for all purposes.
    SUMMARY Compositions and methods for inserting a target into a Rosa gene locus are disclosed here. The compositions and methods described in this document can be used for genome editing, including, among others: cleavage of one or more genes in an animal cell, resulting in targeted alteration (insertion, deletion and / or substitution mutations) in one or more genes, including the incorporation of these targeted changes in the germline; targeted introduction of non-endogenous nucleic acids, complete or partial inactivation of one or more genes in an animal; homology-directed repair induction methods, generation of transgenic animals (eg, rodents) and / or generation of random mutations that encode new allelic forms of animal genes. In one aspect, a finger zinc protein (ZFP) is described here that binds to the target site in a Rosa gene in a genome (for example, a rodent genome), wherein the ZFP comprises one or more domains of zinc finger link designed. In one embodiment, the ZFP is a zinc finger nuclease (ZFN) that cleaves a target genomic region of interest, where the ZFN comprises one or more projected zinc finger binding domains and a nuclease cleavage domain or medium cleavage domain. Cleavage domains and half cleavage domains can be obtained, for example, several restriction endonucleases
    3/39 and / or endonuclease housing. In one embodiment, the half-cleavage domains are derived from a restriction endonuclease of the IIS type (for example, Fok 1). In certain modalities, the zinc finger domain recognizes a target site in a Rosa gene, for example, Rosa26.
    The ZFN can bind and / or cleave a Rosa gene within the co-complicating region of the gene or in a non-coding sequence within or adjacent to the gene, such as, for example, a leader sequence, trailer or intron sequence, or within a non-transcribed region, upstream or downstream of the coding region.
    In another aspect, compositions comprising one or more of the zinc finger nucleases described herein are described herein. In certain embodiments, the composition comprises one or more zinc finger nucleases in combination with a pharmaceutically acceptable excipient.
    In another aspect, a polynucleotide that encodes one or more ZFNs described herein is described herein. The polynucleotide can be, for example, MRNA.
    In another aspect, a ZFN expression vector comprising a polynucleotide encoding one or more ZFNs described herein, operably linked to a promoter, is described herein.
    In another aspect, a host cell comprising one or more ZFN expression vectors as described herein is described herein. The host cell can be transformed stably or transiently transfected or a combination thereof with one or more ZFP expression vectors. In one embodiment, the host cell is an embryonic stem cell. In other embodiments, the one or more ZFP expression vectors express one or more ZFNs in the host cell. In another embodiment, the host cell may also include an exogenous polynucleotide donor sequence. In any of the embodiments, described herein, the host cell may comprise an embryonic cell, for example, one or more embryonic cells from mice, rabbits or other mammals.
    In another aspect, a method is described here for cleaving one or
    "4/39 more Rosa genes in a cell, the method comprising: (a) introducing into the cell one or more polynucleotides that encode one or more ZFNs that bind to a target site one or more genes under conditions such that a ( s) ZFN (s) is (are) expressed (s) and the one or more genes are cleaved.
    In yet another aspect, a method for introducing an exogenous sequence into the genome of a cell is described here, the method comprising the steps of: (a) introducing into the cell one or more polynucleotides that encode one or more more ZFNs that bind to a target site in a Rosa gene under conditions such that the ZFN (s) is (are) expressed (s) and one or - 10 more genes are cleaved; and (b) contacting the cell with an exogenous polynucleotide; this cleavage of the genes stimulates the integration of exogenous polynucleotide ”in the genome by homologous recombination. In certain embodiments, the exogenous polynucleotide is physically integrated into the genome. In other modes, the exogenous polynucleotide is integrated into the genome by copying from the exogenous sequence in the genome of the host cell through replication | cation of nucleic acid (for example, homologous repair of double strand break). In still other modalities, integration into the genome occurs through targeted integration dependent on non-homology (for example "end capture"). In certain embodiments, one or more nucleases are fusions between the cleavage domain of an IIS-type restriction endonucleosis and a projected zinc finger binding domain. In certain embodiments, the exogenous sequence is integrated into the Rosa gene of a small mammal (for example, rabbit or rodent such as mouse, mouse, etc.).
    In another embodiment, a method for modifying one or more Rosa gene sequences in the cell genome is described herein, the method comprising (a) providing a cell comprising one or more Rosa sequences; and (b) expressing first and second zinc finger nucleases (ZFNs) in the cell, where the first ZFN cleaves at a cleavage site and the second ZFN cleaves at a second cleavage site, where the gene sequence is located between the first cleavage site and the second cleavage site, where the cleavage of the first and second cleavage sites
    '5/39 results in modification of the gene sequence by non-homologous end ligation and / or homology-directed repair. Optionally, the cleavage results in the insertion of an exogenous sequence (transgene) also introduced into the cell. In other embodiments, the non-homologous end joint results in a deletion between the first and second cleavage sites. The size of the gene sequence deletion is determined by the distance between the first and second cleavage sites. In this sense, deletions of any size, in any genomic region of interest, can be obtained. Deletions of 25, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 nucleotide pairs, or any integral value of ”nucleotide pairs within this range, can be obtained. In addition, - deletions of a sequence of any integral value of nucleotide pairs greater than 1,000 nucleotide pairs can be obtained using the methods and compositions disclosed here.
    Methods to modify an endogenous Rosa gene as described | here they can be used to create models of animal disease (eg, human), for example, inactivating (partially or totally) a gene or creating random mutations at defined gene positions that allow the identification or selection of transgenic animals (for example, rats, rabbits or mice) conducted new allelic forms of those genes, by | insertion of humanized genes (to study, by means of a non-limiting example, drug metabolism) or insertion of mutant alleles to assess, for example, the phenotype affect of said mutant allele.
    In yet another aspect, a method is described here for disrupting germline of one or more Rosa target genes, the method comprising modifying one or more Rosa sequences in the genome of one or more cells of an embryo by any of the methods described here and allowing the embryo develops, in which the modified gene sequences are present in at least part of the sexually mature animal's gametes. In certain embodiments, the animal is a small mammal, such as a rodent or rabbit.
    In another aspect, a method of creating one or more hereditary mutant alleles in at least one Rosa locus of interest is described here, the method comprising modifying one or more Rosa loci in the genome of one or more cells of an animal embryo by any of the methods | described here; bringing the embryo to sexual maturity; and allowing | the sexually mature animal produces offspring; at least | some of the descendants comprise the mutant alleles.
    In certain modalities, the animal is a small mammal, for example a rabbit or rodent like a rat, a mouse, or a guinea pig.
    In any of the methods described herein, the linucleotide polypeptide encoding the zinc finger nuclease (s) may comprise DNA, RNA or combinations thereof.
    In certain embodiments, the polynucleotide comprises a plasmid.
    In other embodiments, the polynucleotide that encodes the nucleasse comprises mRNA.
    In yet another aspect, a method of site-specific integration of a nucleic acid sequence into a locus is presented here! Pink of a chromosome.
    In certain embodiments, the method comprises: (a) injecting an embryo with (i) at least one DNA vector, where the DNA vector comprises an upstream and a downstream sequence flanking the nucleic acid sequence to be integrated , and (ii) at least one RNA molecule encoding a zinc finger nuclease that recognizes the integration site at the Rosa locus, and (b) culturing the embryo to allow expression of the zinc finger nuclease, in that a double-strand break introduced at the zinc finger nuclease integration site is repaired, through homologous recombination with the DNA vector, in order to integrate the nucleic acid sequence into the chromosome.
    Appropriate embryos can be derived from a variety of vertebrate species, including mammals, birds, reptiles, amphibians and fish species.
    In general, an appropriate embryo is an embryo that can be collected, injected and cultured to allow the expression of a zinc finger nuclease.
    In some embodiments, appropriate embryos may include embryos of small mammals (eg, rodents, rabbits, etc.), companion animals, livestock animals and primates.
    Examples are not limited
    ] 71/39 rodents can include mice, rats, hamsters, gerbils and guinea pigs.
    Non-limiting examples of pets can include cats, dogs, rabbits, hedgehogs and ferrets.
    Non-limiting examples of livestock animals may include horses, goats, sheep, pigs, llamas, alpacas and cattle.
    Non-limiting examples of primates may include capuchin monkeys, chimpanzees, lemurs, monkeys, marmosets, monkeys, spider monkeys, squirrel monkeys and vervet monkeys.
    In other embodiments, appropriate embryos may include embryos from fish, reptiles, amphibians and birds.
    As an alternative, the appropriate embryos can be insect embryos, for example, a Drosophila embryo or a mosquito embryo.
    Ú An embryo is also provided comprising at least - one DNA vector, where the DNA vector comprises an upstream and downstream sequence flanking the nucleic acid sequence to be integrated, and at least one RNA molecule encoding a zinc finger nu- clease that recognizes the chromosomal integration site.
    Organisms derived from any of the embryos as described here! are also provided.
    A kit, comprising the ZFPs of the invention, is also provided.
    The kit may comprise nucleic acids encoding ZFPs, (for example RNA molecules or genes encoding ZFP contained in an appropriate expression vector), donor molecules, appropriate host cell lines, instructions for carrying out invention and the like.
    Brief Description of the Drawings Figure 1 represents a Southern blot showing the results of the NHEJ repair after cleavage of the rat pink locus26 as tested by the Surveyor "Y (Transgenomic) incompatibility test." G "indicates reactions where the cells were transfected with GFP ZFNs, and numbered lanes indicate specific pairs of ZFN.
    The arrows indicate clues where —NHEJ occurred.
    Figure 2 represents the insertion of donor nucleotides targeted at Rosa in mouse genomic DNA.
    '8/39
    DETAILED DESCRIPTION Compositions and methods for genomic editing in (for example, small mammals such as mice, rats or rabbits) (for example, cleavage of genes; alteration of genes, for example by cleavage followed by insertion (physical insertion or replication insertion through homology-directed repair) of an exogenous sequence and / or cleavage followed by non-homologous extremity union (NHEJ); partial or complete inactivation of one or more genes; generation of alleles with random mutations to create expression of endogenous genes, etc.) and changes in the genome that are carried out in the germ line. Also disclosed are methods for producing and using these compositions (reagents), for example, to edit (alter) one or more genes in a target animal cell (for example, small mammals). Thus, the methods and compositions described here provide highly efficient methods for the alteration of the targeted gene (for example, knock-in) and / or knockout (partial or | complete) of one or more genes and / or by random mutation of the sequence of any allele target, and therefore allow the generation of animal models of human diseases. The compositions and methods described here provide rapid, complete and permanent targeted disruption of endogenous loci in animals, without the need for labor-intensive selection and / or screening and with minimal off-target effects. Knockouts of whole animal genes can also be easily generated in a single step by injection of ZFN mRNA or ZFN expression cassettes. General The practice of the methods, as well as the preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques of molecular biology, biochemistry, chromatin structure and computational chemical analysis, cell culture, recombinant DNA , and related fields as they are within the skill of the expert in the technique. These techniques are explained entirely in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATO-
    : 9/39 RY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al, CURRENT PROTOCOLS IN MO- LECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic up-dates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, "Chromatin" (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, "Chromatin Protocols" (PB Becker, ed.) Humana Press, Totowa, 1999. Definitions Ú The terms "nucleic acid," "polynucleotide," and "oligonucleotide - are used" interchangeably and refer to a deoxyribunucleotide or ribonucleotide polymer, in linear or circular conformation, and in the form of single or double tape. For the purposes of this disclosure, these terms should not be considered as limiting with respect to | chest to the length of a polymer. The terms may include known analogs of natural nucleotides, as well as nucleotides that are modified in the base, sugar, and / or phosphate fractions (for example, phosphorotic structures). In general, a particular nucleotide analog has the same base pairing specificity; that is, an analogue of A will generate base pair with T.
    The terms "polypeptide," "peptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally occurring amino acids.
    "Binding" refers to a sequence-specific, non-covalent interaction between macromolecules (for example, between a protein and a nucleic acid). Not all components of a binding interaction need to be sequence specific (for example, contacts with the phosphate residues of a DNA structure), as long as the interaction as a whole is sequence specific. Such interactions are generally
    '10/39 characterized by a dissociation constant (Ka) of 10º M' or less. "Affinity" refers to the binding strength: increased binding affinity being correlated with a lower Ka. | A "binding protein" is a protein that is capable of | i- | | 5 not covalently to the other molecule.
    A binding protein can | | bind to, for example, a DNA molecule (a DNA binding protein), an RNA molecule (an RNA binding protein) and / or a | protein molecule (protein-binding protein). In the case of a pro- | protein binding protein, which can bind itself (to form ho- - 10 modimers, homotrimers, etc.) and / or can bind to one or more molecules | of a different protein or proteins.
    The binding protein may have more | - than a type of liaison activity.
    For example, zinc finger proteins have DNA binding, RNA binding and protein binding activity. | A "DNA-binding finger zinc protein" (or binding domain) is a protein within a larger protein, which binds to a larger protein, which binds to DNA in a specific sequence way through a or more zinc fingers, which are regions of the amino acid sequence within the binding domain whose structure is stabilized through the coordination of a zinc ion.
    The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
    Zinc finger binding domains can be "designed" to bind a predetermined nucleotide sequence.
    Non-limiting examples of methods for engineered zinc finger proteins are designed and selected.
    A projected zinc finger protein is a protein that does not occur in nature whose design / composition results mainly from rational criteria.
    Rational criteria for the project include the application of substitution rules and computerized algorithms for processing information in an information store database of existing ZFP projects and binding data.
    See, for example, US Patents 6,140,081; 6,453,242; and 6,534,261; see further WO 98/53058;
    11/39 WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496.
    A "selected" zinc finger protein is a protein in nature whose production results mainly from an empirical process such as phage display, interaction trap or hybrid selection. See, for example, US 5,789,538; US 5,925,523; US 6,007,988; US 6,013,453; US
    6,200,759; WO 95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970 WO 01/88197 and WO 02/099084. The term "sequence" refers to a nucleotide sequence of any length, which can be DNA or RNA; it can be linear, circular or branched and it can be single or double tape. The term "donor sequence" refers to a nucleotide sequence that is inserted into a - genome. A donor sequence can be any length, for example | example, between 2 and 10,000 nucleotides in length (or any integer between or above these), preferably between 100 and 1,000 | nucleotides in length (or any integer in between), more preferably between about 200 and 500 nucleotides in length.
    A "homologous non-identical sequence" refers to a first sequence that shares a degree of sequence identity with a second sequence, but whose sequence is not identical to that of the second sequence. For example, a polynucleotide that comprises the wild type sequence of a mutant gene is homologous and not identical to the sequence of the mutant gene. In certain embodiments, the degree of homology between the two sequences is sufficient to allow homologous recombination between them, using normal cellular mechanisms. Two non-identical homologous sequences can be of any length and their degree of non-homology can be as small as a single nucleotide (for example, for the correction of a point genome mutation by targeted homologous recombination) or as large as 10 or more kilobases (for example, by inserting a gene into a predetermined ectopic location on a chromosome). Two polynucleotides comprising non-identical homologous sequences need not be the same length. For example, an exogenous polynucleotide (ie, donor polynucleotide) between and ... Ns ... bnc ee. “Cms n - sG" 2.º “ºÊ0.) - ICC ss - / úaSP * iciã" and "[! I222" 2 ". '12/39 20 and 10,000 nucleotides or nucleotide pairs can be used.
    Techniques for determining nucleic acids and amino acid sequence identity are known in the art. Typically, these techniques include determining the nucleotide sequence of the —mRNA for a gene and / or determining the amino acid sequence encoded by it, and comparing these sequences to a second nucleotide or amino acid sequence. Genomic sequences can also be determined and compared in this way. In general, identity refers to an exact nucleotide-to-nucleotide or amino acid-a- match: 10 amino acids of two polynucleotides or polypeptide sequences, respectively. Two or more sequences (polynucleotides or amino acids) can be compared when determining their identity percentage. The identity percentage of two sequences, nucleic acid sequences or amino acids, is the number of exact matches between two aligned sequences divided by the length of the shortest sequences and multiplied by 100.
    Alternatively, the degree of sequence similarity between polynucleotides can be determined by polynucleotide hybridization, under conditions that allow the formation of stable double homologous regions, followed by digestion with specific single-stranded nucleases and determination of fragment size digested. Two nucleic acids, or two polypeptide sequences are substantially homologous to each other as the sequences are at least about 70% -75%, preferably 80% -82%, more preferably 85% -90%, even more preferred preferably 92%, even more preferably 95%, and most preferably 98% sequence identity over a defined length of the molecules, as determined using the methods above. As used herein, substantially homologous also refers to sequences that show complete identity of a specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment in, for example , strict conditions, as defined for that particular system. The definition
    O O RSDPÇPPsss. — 2Ç. “- Oops eee eee aaa .... pré nn A Ob:] JC O âÍ "“ º ““ O .õ! ”“ “" ““ “6i“ ”1IIN“ º ““ “éj'oo" | 7 13/39 |: | of hybridization conditions is within the skill of the technician.
    See, for example, Sambrook et al., Supra; Nucleic Acid Hybridization: A Practical Approach, editors B.D.
    Hames and S.J.
    Higgins, (1985) Oxford; Washington, DC; IRL Press). Selective hybridization of two nucleic acid fragments can be determined as follows.
    The degree of sequence identity between two nucleic acid molecules affects the efficiency and hybridization force events between said molecules.
    A partially identical nucleic acid sequence will at least partially inhibit the hybridization of one: 10 completely identical sequence to a target molecule.
    Inhibition of completely identical sequence hybridization can be assessed using - hybridization assays that are well known in the art (for example, Southern (DNA) blot, Northern blot (RNA), solution hybridization, or the like, see Sambrook, et al., Molecular Cloning: A Laboratory Manual, Condition Edition, (1989) Cold Spring Harbor, NY). Such tests can be carried out using varying degrees of selectivity, for example, using different conditions from low to high rigor.
    If low-risk conditions are employed, the absence of non-specific binding can be assessed using a secondary probe, which still lacks a partial degree of sequence identity (for example, a probe containing less than about 30% sequence identity with the target molecule), so that, in the absence of non-specific binding events, the secondary probe will not hybridize to the target.
    When using a hybridization-based detection system | tion, a nucleic acid probe is chosen that is complementary to a reference nucleic acid sequence and then, through the selection of suitable conditions, the probe and reference sequence selectively hybridize or bind to each other to form a double molecule.
    A nucleic acid molecule that is able to selectively hybridize to a reference sequence, under moderately stringent hybridization conditions, typically hybridizes under conditions that allow the detection of a target nucleic acid sequence of at least about 10-
    A + 14/39 14 nucleotides in length with at least about 70% sequence identity with the selected nucleic acid probe sequence.
    Strict hybridization conditions typically allow detection of! target nucleic acid sequences of at least about 10-14 nucleotides in length containing a sequence identity of more than about 90-95% with the selected nucleic acid probe sequence.
    The hybridization conditions useful for the probe / reference sequence hybridization, where the probe and the reference sequence have one; specific degree of sequence identity, can be determined as is | known in the art (see, for example, Nucleic Acid Hybridization: A Practice: cal Approach, editors B.D.
    Hames and S.J.
    Higgins, (1985) Oxford; Washington, DC; IRL Press). Hybridization conditions are well known to those skilled in the art.
    Hybridization stringency refers to the degree to which hybridization conditions favor the formation of hybrids that contain incorrect nucleotides, with greater stringency correlated with a low tolerance for the incorrect hybrids.
    Factors affecting the stringency of hybridization are well known to those skilled in the art and include, among others, temperature, pH, ionic strength, and concentration of organic solvents such as formamide and dimethyl sulfoxide.
    As is known to those skilled in the art, stringency of hybridization is increased by higher temperatures, lower ionic strength and lower concentrations of solvents.
    With regard to stringent hybridization conditions, it is well known in the art that numerous equivalent conditions can be used to establish a particular stringency, varying, for example, the following factors: the length and nature of the sequences, the basic composition of the various sequences, the concentrations of salts and other components of the hybridization solution, the presence or absence of blocking agents in the hybridization solutions (for example, dextran sulfate, and polyethylene glycol), the temperature of the hybridization reaction and the time parameters as well as different washing conditions.
    The selection of a con- | particular set of hybridization conditions is selected according to
    PPP qq aossppasssaapapeereeereee and --rrrrsri-rv ÚP * A ““ omsÉêé ii OO '15/39 | standard methods in the art (see, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, NY). "Recombination" refers to a process of exchanging genetic information between two polynucleotides. For the purposes of this disclosure, "homologous combination (HR)" refers to the specialized form of said exchange that occurs, for example, during repair of double-strand breaks in cells through homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a "donated '10" molecule to repair the mold of a "target" molecule (that is, the one that experiences double strand breaking), and is varied known as "conversion of - gene without crossover" or "conversion of gene of short stroke," due to lead to the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, transference may involve heteroduple DNA mismatch correction that forms between the broken target and the donor, and / or "synthesis-dependent ribbon ringing," in which the donor is used to resynthesize genetic information that will be part of the target, and / or related processes. Said specialized HR generally results in a change in the sequence of the target molecule so that part or all of the donor polynucleotide sequence is incorporated into the target polynucleotide.
    In the methods of the present disclosure, one or more specific nucleases described herein as creating a double-stranded break in the target sequence (for example, cell chromatin) at a predetermined location, and a "donor" polylucleotide, containing homology to the nucleotide sequence in the break region, it can be introduced into the cell. The presence of the double chain break has been shown to facilitate the integration of the donor sequence. The donor sequence can be physically integrated or, alternatively, the donor polynucleotide is used as a model for repairing the break through homologous recombination, which results in the introduction of all or part of the nucleotide sequence as in the donor into chromatin cell phone. In this way, a first cell chromatin sequence can be altered
    | . 16/39 and, in certain modalities, can be converted into a sequence present in a donor polynucleotide. Thus, the use of the terms "substitute" or "substitution" can be understood to represent the substitution of one nucleotide sequence for another, (that is, substitution in the sense of information), and does not necessarily require physical or chemical substitution of one polynucleotide on the other.
    In any of the methods described herein, additional pairs of zinc finger proteins can be used for additional double-stranded cleavage of additional target sites within the cell.
    R 10 In certain modalities of methods for directed recombination and / or substitution and / or alteration of a sequence in a region. interest in cell chromatin, a chromosomal sequence is altered by homologous recombination with an exogenous "donor" nucleotide sequence. Said homologous recombination is stimulated by the presence of a double chain break in the cell chromatin, if sequences homologous to the region of the break are present.
    In any of the methods described here, the first nucleotide sequence (the "donor sequence") can contain sequences that are homologous, but not identical, to the genomic sequences in the region of interest, thus stimulating homologous recombination to insert the non-identical sequence in the region of interest. Thus, in certain embodiments, the portions of the donor sequence that are homologous to the sequences in the region of interest have between about 80 to 99% (or any integer between them) sequence identity for the genomic sequence that is substituted.
    In other modalities, the homology between the donor and the genomic sequence is greater than 99%, for example, if only a different nucleotide as between donor and genomic sequences of more than 100 contiguous base pairs. In certain cases, a non-homologous portion of the donor sequence may contain sequences that are not present in the region of interest, such that new sequences are introduced in the region of interest. In these cases, the non-homologous sequence is generally flanked by sequences of 50-1000 base pairs (or any integral value between
    SS | (17/39 same) or any number of base pairs greater than 1000, which are homologous or identical to the sequences of the region of interest.
    In other modalities, the donor sequence is not homologous to the first sequence, and is inserted into the genome by non-homologous recombination mechanisms.
    Any of the methods described here can be used for partial or complete inactivation of one or more target sequences of a cell by integration directed to the donor sequence that disrupts the expression of the gene of interest.
    Cell lines with partially or '10 completely inactivated genes are also provided.
    In addition, the targeted integration methods as - described here can also be used to integrate one or more exogenous sequences.
    The exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules or any type of coding or non-coding sequence, as well as one or more control elements (for example, promoters). In addition, the exogenous nucleic acid sequence can produce one or more RNA molecules (for example, small hairpin RNAs (ShRNAs), inhibitory RNAs (RNAis), microRNAs (mMIiRNAs), etc.). "Cleavage" refers to the breakdown of the covalent structure of a DNA molecule.
    Cleavage can be initiated by a variety of methods | including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond.
    Single-strand cleavage and double-strand cleavage are possible and double-strand cleavage may occur as a result of two distinct single-strand cleavage events.
    DNA cleavage can result in the production of blunt or staggered ends.
    In certain embodiments, fusion polypeptides are used for cleavage of so-called double-directed DNA.
    A "half-cleavage domain" is a polypeptide sequence that, together with a second polypeptide (identical or different) forms a complex containing cleavage activity (preferably double-stranded cleavage activity). The terms "first and second means do-
    . 18/39 | minimum cleavage; "" + and - half cleavage domains "and" direct and left half cleavage domains "are used interchangeably to refer to the pairs of half cleavage domains that dimerize.
    A "projected cleavage half-domain" is a half-cleavage domain that has been modified to form mandatory heterodimers with another half-cleavage domain (for example, another half-cleavage domain). See also US patent publication. 2005/0064474; 2007/0218528 and 2008/0131962, incorporated herein by reference in their entirety.
    Í. 10 "Chromatin" is a nucleoprotein structure comprising the cell genome.
    Cell chromatin is composed of nucleic acid, mainly DNA and proteins, including histone and non-histone chromosomal proteins.
    Most eukaryotic cell chromatin exists in the form of nucleosomes, in which a nucleosome nucleus comprises about 150 base pairs of DNA associated with an octamer consisting of | two of histones H2A, H2B, H3 and H4; and ligating DNA (of variable length, depending on the organism) extends between nucleosome nuclei. | A histone H1 molecule is usually associated with the DNA ligand.
    For the purposes of the present disclosure, the term "chromatin" is intended to include all types of cellular nucleoprotein, both eukaryotic and prokaryotic.
    Cell chromatin includes chromosomal and episomal chromatin.
    A "chromosome" is a chromatin complex comprising all or a portion of a cell's genome.
    A cell's genome is generally characterized by its karyotype, which is the collection of all the chromosomes that make up the cell's genome.
    A cell's genome can comprise one or more chromosomes.
    An "episome" is a replicating nucleic acid, nucleoprotein complex or other structures comprising a nucleic acid that is not part of a cell's chromosomal karyotype.
    Examples of episodes include plasmids and certain viral genomes.
    A "target site" or "target sequence" is a nucleic acid sequence that defines a portion of a nucleic acid to which a molecule
    ] 19/39 connection will connect as long as there are sufficient conditions for connection. For example, the sequence 5-GAATTC-3 'is a target site for the restriction endonucleate Eco RI. An "exogenous" molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. "Normal presence in the cell" is determined with respect to the particular stage of development and environmental conditions of the cell. So, for example, a molecule that is only present during embryonic muscle development is an exogenous molecule with respect to an adult muscle cell. In the same way, a molecule induced by thermal shock is an exogenous molecule with respect to a shocked cell without heat. An exogenous molecule can include, for example, a working version of a molecule | malfunctioning or malfunctioning version of a normally functioning endogenous molecule. An exogenous molecule can also be a molecule normally found in another species, for example, a human sequence introduced into the animal's genome. | An exogenous molecule can be, among other things, a small molecule, as it is generated by a process of combinatorial chemistry, or a macromolecule such as a protein, nucleic acids, carbohydrates, lipids, glycoprotein, lipoprotein, polysaccharide, any modified derivative. of the above molecules or any complex composed of one or more of the above molecules. DNA and RNA nucleic acids, can be single or double stranded; it can be linear, branched or circular; and can be any length. Nucleic acids include those capable of forming double nucleic acids, as well as forming triple. See, for example, US patent
    5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetyl | 30 lases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, girases and helicases. An exogenous molecule can be the same type of co- |
    SNS 1] 20/39 mo an endogenous molecule, for example, an exogenous protein or nucleic acid.
    For example, exogenous nucleic acid may comprise an infectious viral genome, a plasmid or episome introduced into a cell or a chromosome that is not normally present in the cell.
    Methods for introducing exogenous molecules into cells are known to those skilled in the art and include, among others, lipid-mediated transfer (i.e., liposomes, including cationic and neutral lipids), electroporation, direct injection, cell fusion, particle bombardment , coprecipita- | calcium phosphate, DEAE-dextran-mediated transfer and trans- | . 10 ference mediated by viral vector. | On the other hand, an "endogenous" molecule is one that is normally present in a particular cell in the development stage; under particular environmental conditions.
    For example, an endogenous nucleic acid may comprise a chromosome, the genome of a mitochondria, —chloroplast or another organelle or naturally occurring episomal nucleic acids.
    Additional endogenous molecules can include proteins, for example, enzymes and transcription factors.
    A "fusion" molecule is a molecule in which two or more subunit molecules are preferably linked covalently.
    The subunit molecules can be the same type of chemical as the molecule, or they can be different chemical types of molecules.
    Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP DNA binding domain and a cleavage domain) and fusion nucleic acids (for example, an acid nu-: kleic encoding the fusion protein described above). Examples of the second type of fusion molecule include, among others, a fusion between triple-formed nucleic acids and a polypeptide and a fusion between a binder | minor groove and a nucleic acid.
    The expression of a fusion protein in a cell can result from the release of the fusion protein into the cell or by the release of a polynucleotide that encodes the fusion protein into a cell, where the polynucleotide is transcribed and the transcription is translated, to generate the protein
    ] 21/39 of merger. Transprocessing, polypeptide cleavage and polypeptide binding can be involved in the expression of a protein in a cell. Methods for delivering polynucleotide and polypeptide to cells are presented elsewhere in this disclosure.
    A "gene," for the purposes of the present disclosure, includes a region of DNA that encodes a product of the gene (see below), as well as all regions of DNA that regulate the production of a gene product, whether or not said regulatory sequences are adjacent to the coding and / or transcribed sequences. Thus, a gene includes, but is not necessarily limited to: 10a, promoter sequences, terminators, translation regulatory sequences, such as ribosome binding sites and internal ri entry sites. bossomo, breeders, mufflers, insulators, insulating elements, origins of replication, sites of connection to the matrix and control regions of the locus. "Gene expression" refers to the conversion of information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (for example, mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translating an mRNA. Gene products also include RNAs that are modified by processes such as capping, polyadenylation, methylation and editing and modified proteins, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristylation and glycosylation.
    "Modulation" of gene expression refers to the change in the activity of a gene. Modulation of expression may include, but is not limited to, gene activation and gene suppression. Genome editing (for example, cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression compared to a cell that does not include a ZFP as described here. Thus, the gene inactivation can be partial or total.
    A "region of interest" is any cell chromatin region, such as, for example, a non-coding gene or sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. THE
    ] 22/39 1 of recombination binding may be for the purpose of cleavage of target DNA and / or 'te in a chromosome-targeted. A region of interest may be present, mitochondrial, cloomatous, an episome, an organellar genome (for example an interplast region) or an infectious viral genome, for example. U within the 5 regions can be within the coding region of a gene, leader, transcribed non-coding sequences such as, for example, sequencing or downstream of the trailer or introns, or non-transcribed regions, the small assembly as a coding region. A region of interest can be as typical in length of single nucleotides, or up to 2000 pairs of nuclec S. j 10 ment, or any integral value of nucleotide pairs: Illy linked "(or The terms" operative link "and" unbending operations with reference - | "operationally connected") are used interceptively (as elements referring to a juxtaposition of two or more components: and both sequentially), in which the components are arranged d.
    the possibility that the components function normally and allow the action that is exercised by at least one of the components can mediate a function, one by at least one of the other components. As a | peratively is | regulatory transcription sequence, such as a promoter, o: transcriptional linker to a coding sequence if the re-encoded sequence under control controls the transcription level of the transcriptional sequence to the presence or absence of one or more factors of | operatively- description. A transcriptional regulation sequence is ge:, but it does not need to be cis-linked with an orator coding sequence, it is a serice directly adjacent to it. For example, a honey is linked to a transcriptional regulatory sequence that operatively Ss. coding sequence, even if they are not contiguous "With respect to the fusion polypeptides, the terpponents perform the bonding" can refer to the fact that each of the cons could be the same function in connection with another component according to the fu- 30 polypeptide, if not linked. For example, with respect to a healthy domain where a ZFP DNA binding domain is cleavage fused, the ZFP DNA binding domain and the
    ] 23/39 in operative binding if, in the fusion polypeptide, the portion of the ZFP DNA binding domain is able to bind to its target site and / or its binding site | while the cleavage domain is able to cleave DNA in the neighborhood | of the target site. | 5 A "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid that is not identical to the full-length protein, polypeptide or nucleic acid, yet retains | same function as full-length protein, polypeptide or nucleic acid.
    A functional fragment can have more, less, or the same. 10 number of residues as the corresponding native molecule, and / or may contain one or more amino acids or nucleotide substitutions.
    Methods for. determination of the function of a nucleic acid (eg, coding function, ability to hybridize to another nucleic acid) are well known in the art.
    Similarly, methods for determining function | 15 of the protein are well known.
    For example, the DNA-binding function of a polypeptide can be determined, for example, by changing electrophoretic mobility, filter-binding, or immunoprecipitation assays. | DNA cleavage can be analyzed by gel electrophoresis.
    See Ausubel et al., Supra.
    The ability of a protein to interact with another protein can be determined, for example, by coprecipitation, two-hybrid assays or complementation, both genetic and biochemical.
    See, for example, Fields et al. (1989) Nature 340: 245-246; US patent 5,585,245 and PCT WO 98/44350. Zinc Finger Nucleases Zinc finger nucleases (ZFNs) that can be used for genomic editing (e.g., cleavage, alteration, inactivation and / or random mutation) of one or more Rosa genes are described herein.
    ZFNs comprise a zinc finger protein (ZFP) and a nuclease domain (cleavage) (e.g., half a cleavage domain). THE.
    Finger zinc proteins | Zinc finger binding domains can be designed to bind to a sequence of choice.
    See, for example, Beerli et a /. (2002) Na-
    | Ú 24/39 ture Biotechnol. 20: 135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70: 313- 340; Isalan et al. (2001) Nature Biotechnol. 19: 656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12: 632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10: 411-416. A designed zinc finger binding domain may have a new binding specificity compared to a finger protein | naturally occurring zinc. Engineering methods include, but are not limited to, | rational design and various types of selection. The rational design includes, for example, using databases comprising triplet (or quadruple) nucleotide sequences and individual finger amino acid sequences: 10 zinc, where each triplet or quadruple nucleotide sequence is associated with one or more zinc finger amino acid sequences that 7 bind to a particular triplet or quadruple sequence. See, for example, US co-ownership patents 6,453,242 and 6,534,261, incorporated by reference here in their entirety. Specimen selection methods, including phage display and two hybrid systems, are disclosed in US Patents 5,789,538;
    5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and
    6,242,568; as well as WO 98/37186; WO 98/53057; WO 00/27878; WO | 01/88197 and GB 2,338,237. In addition, the improved binding specificity for zinc finger binding domains has been described, for example, in co-ownership WO 02/077227.
    Selection of target sites; ZFPs and methods for designing and building fusion proteins (and polynucleotides encoding the same) are known to those skilled in the art and described in detail in publication | 25 of US patent application 20050064474 and 20060188987, incorporated by reference in its entirety here. | In addition, as revealed in these and other references, zinc finger domains and / or multi-finger zinc finger proteins can be linked together using appropriate linker sequences, including, by | For example, linkers of 5 or more amino acids in length (for example, | TGEKP (SEQ ID NO: 1), TGGQRP (SEQ ID NO: 2), TGQKP (SEQ ID NO: 3), | and TGSOKP (SEQ ID NO : 4)) See also US patent 6,479,626;
    : 25/39 '6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length.
    The proteins described here can include any combination of appropriate ligands between the individual zinc fingers of the protein. | 5 As described below, in certain embodiments, a four, five, or six-finger binding domain is fused to a half-cleavage domain, such as the cleavage domain of a lls-like restriction endonuclease such as Fok |. One or more zinc finger / nuclease half-domain fusions are used for targeted cleavage, as: 10 disclosed, for example, in US patent publication 20050064474. For targeted cleavage, the edges close to the alloy sites -. can be separated by 5 or more pairs of nucleotides and each of the fusion proteins can bind to an opposite strand of target DNA.
    All | paired combinations 1 can be used for targeted cleavage | 15 of a Rosa gene.
    After the present disclosure, ZFNs can be targeted to any sequence in the animal's genome. 'In some embodiments, the DNA binding domain is a projected domain of a TAL effector derived from a Xanthomonas plant pathogen (see Boch et a /, (2009) Science 326: 1509-1512 and Moscow and Bogdanove, (2009) Science326: 1501). B.
    Cleavage Domains Í ZFNs also make up a nuclease (cleavage domain, half cleavage domain). The cleavage domain part of the fusion proteins disclosed herein can be obtained from any endonuclease or - exonuclease.
    Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases.
    See, for example, 2002-2003 Catalog, New Engineering Biolabs, Beverly, MA; and Belfort et al. (1997) Nucleic Acids Res. 25: 3379-3388. Additional enzymes that cleave DNA are known (for example, S1 Nuclease; mung bean nuclease; pancreatic DNase |; micrococcal nuclease; yeast HO endonuclease; see also Linn et al. (Eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). One or more
    26/39 of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and half cleavage domains. Similarly, a half domain cleavage can be derived from any nuclease or part thereof, as defined above, which requires dimerization for cleavage activity. In general, two fusion proteins are required for cleavage if the fusion proteins comprise half-cleavage domains. Alternatively, a single protein comprising two half cleavage domains can be used. The two half cleavage domains can be derived from the same en-. 10 donuclease (or functional fragments thereof), or each half cleavage domain can be derived from a different endonuclease (or fragments - functional thereof). In addition, the target sites for the two fusion proteins are preferably arranged, with respect to each other, so that the binding of two fusion proteins to their respective target sites of the half cleavage domains in a spatial orientation to each other that it allows the means of cleavage domains to form a functional cleavage domain, for example, by dimerization. Thus, in certain embodiments, the edges close to the target sites are separated by 5-8 nucleotides or 15-18 nucleotides. However, any integer number of nucleotide pairs or nucleotides can intervene between two target sites (for example, from 2 to 50 pairs of nucleotides or more). In general, the cleavage site is between the target sites.
    Restriction endonucleases (restriction enzymes) are present in many species and are capable of specific sequence binding to DNA (at a recognition site), and DNA cleavage at or near the binding site. Certain restriction enzymes (for example, type IIS) cleave DNA at sites removed from the recognition site and have separable domains and binding domains. For example, the enzyme type IIS Fok |, which catalyzes double-stranded DNA cleavage, in 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, US Patents 5,356,802; 5,436,150 and
    5,487,994; as well as Li et a /. (1992) Proc. Natl. Acad. Sci. USA 89: 4275-
    27/39 4279; Li et al. (1993) Proc. Natl. Acad. Sci. USA 90: 2764-2768; Kim et al. (1994a) Proc. Natl. Acad. Sci. USA 91: 883-887; Kim et al. (1994b) J. Biol. Chem. 269: 31,978-31,982. Thus, in one embodiment, fusion proteins comprise the cleavage domain (or half cleavage domain) from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which can be or not designed.
    An exemplary IIS type restriction enzyme, whose cleavage domain is separable from the binding domain, is Fok |. This particular enzyme is active as a dimer. Bitinaite et a /. (1998) Proc. Natl. Acad. Sci. USA 95:: 10 10,570-10,575. Thus, for the purposes of this disclosure, the Fok | used in revealed fusion proteins is considered a domestic medium. cleavage. Thus, for double-stranded cleavage and / or targeted replacement of cell sequences using zinc-finger-Fok | fusions, two fusion proteins, each comprising a half Fok | cleavage domain, can be used to reconstitute a catalytically active cleavage domain. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two half Fok cleavage domains | can also be used. Targeted cleavage parameters and targeted sequence change using Fok zinc finger fusions | they are provided elsewhere in the revelation.
    A cleavage domain or half cleavage domain can be any part of a protein that retains cleavage activity or that retains the ability to multimerize (for example, dimerize) to form a functional cleavage domain.
    Type IIS restriction enzymes are described in International Publication WO 07/014275, incorporated here in their entirety. Additional restriction enzymes still contain separable binding and cleavage domains, and these are contemplated by the present disclosure. See, for example, Ro- | berts et al. (2003) Nucleic Acids Res. 31: 418-420.
    In certain embodiments, the cleavage domain comprises one or more half-designed cleavage domains (still referred to as dimerization domain mutants) that minimize or prevent homologation.
    28/39 dimerization, as described, for example in US patent publication 20050064474; 20060188987 and 20080131962, the disclosures of which are all incorporated by reference in their entirety here. Amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496,498,499,500,531, 534, 537 and 538 of Fok | they are all targets to influence dimerization of half Fok | cleavage domains.
    Exemplary projected cleavage domains of Fok | forming mandatory heterodimers include a pair in which a first half cleavage domain includes mutations in amino acid residues at: 10 positions 490 and 538 of Fok | and a second half cleavage domain includes mutations in amino acid residues 486 and 499.
    . Thus, in one embodiment, a 490 mutation replaces Glu (E) with Lys (K); the 538 mutation replaces Iso (1) with Lys (K); the 486 mutation replaces Gln (Q) with Glu (E); and the mutation at position 499 replaces Iso (l) with Lys (K). Specifically, the projected half-cleavage domains described here were prepared by mutant positions 490 (EK) and 538 (I—> K) in a half-cleavage domain to produce a half-designed cleavage domain designated "E490K: 1538K" and by mutant positions 486 (QE) and 499 (IL) in another half cleavage domain to produce a designed half cleavage domain designated "Q486E: / 1499L". The half-projected cleavage domains described here are mandatory heterodimer mutants in which abnormal cleavage is minimized or abolished.
    See, for example, Example 1 of WO 07/139898. In certain embodiments, the projected cleavage domain half comprises mutations at positions 486,499 and 496 (numbered in relation to wild type Fok |), for example, mutations that replace the wild type GIn (Q) residue at position 486 | with a Glu residue (E), the wild type Iso (|) residue at position 499 | with a Leu residue (L) and the Asn residue (N) of the wild type at position 496 with an Asp (D) or Glu residue (E) (still referred to as "ELD" and "ELE" domains , respectively). In other modalities, the projected cleavage domain medium comprises mutations at positions 490, 538 and 537 (numbered in relation to Fok | wild type), for example, mutations
    '29/39 replacing the wild type Glu residue (E) at position 490 with a Lys residue (K), the wild type Iso residue (1) at position 538 with a Lys residue (K), and the residue wild type His (H) at position 537 with a Lys residue (K) or an Arg (R) residue (still referred to as "KKK" and "KKR" domains, respectively). In other embodiments, the projected cleavage domain comprises mutations at positions 490 and 537 (numbered in relation to the wild type Fok |), for example, mutations that replace the wild type residue Glu (E) in the position 490 with a Lys residue (K) and the wild type His (H) residue at position 537 with a residue. 10 Lys (K) or an Arg residue (also called "KIK" and "KIR" domains, respectively). (See order US 12 / 931,660).
    . Projected cleavage half-domains described here can be incorporated using any appropriate method, for example, by mutagenesis directed to the wild type cleavage half-domain (Fok |) site as described in US patent publication 20050064474. C. Additional Methods for Targeted Cleavage Any nuclease containing a target site in any Rosa gene can be used in the methods disclosed here. For example, endonucleases homing and meganucleases have very long recognition sequences, some of which are likely to be present, on a statistical basis, once in a human-sized genome. Any said nuclease containing a target site in a Rosa gene can be used instead of, or in addition to, a zinc finger nuclease, for targeted cleavage. Exemplary homing endonucleases include | -Scel, | -Ceul, PI- Pspl, Pl-Sce, I-ScelV, | -Csml, | -Panl, I-Scell, I-Ppol, | -Scelll, | -Crel, | - Tevl, | - | Tevll and | -Tevill. Its recognition strings are known. View | further U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et al. | (1997) Nucleic Acids Res. 25: 3379—3388; Dujon et al. (1989) Gene 82: 115-118; Perler et al. (1994) Nucleic Acids Res. 22, 1125-1127; Jasin (1996) Trends Genet. 12: 224-228; Gimble et al. (1996) J. Mol. Biol. 263: 163-180; Argast et al. (1998) J. Mol. Biol. 280: 345-353 and the New England Biolabs catalog.
    '30/39 Although the specificity of the cleavage of most homing endonucleosis is not absolute in relation to their recognition sites, the sites are of sufficient length that a single cleavage event by mammalian size genome can be obtained expressing an endonuclease homing in a cell containing a single copy of its recognition site. It has also been reported that the specificity of homing endonucleosis and meganucleases can be designed to bind unnatural target sites. See, for example, Chevalier et al. (2002) Molec. Cell 10: 895-905; Epinat et al. (2003) Nucleic Acids Res. 31: 2952-2962; Ashworth et al.
    (2006) Nature 441: 656-659; Paques et al. (2007) Current Gene Therapy: 7: 49-66. . Release ZFNs described herein can be released to a target cell by any suitable means, including, for example, by injection of ZFN MBRNA. See, Hammerschmidt et a /. (1999) Methods Cell Biol. 59: 87-115.
    Protein delivery methods comprising zinc fingers are described, for example, in US patents 6,453,242; 6,503,717;
    6,534,261; 6,599,692, 6,607,882; 6,689,558, 6,824,978; 6,933,113;
    6,979,539; 7,013,219; and 7,163,824, the revelations of all who are incorporated by reference here in their entirety.
    ZFNs as described here can still be released using vectors containing sequences that encode one or more of ZFNs. Any vector system can be used including, among others, plasmid vectors, retroviral vectors, Lentivirus vectors, adenovirus vectors, poxvirus vectors; Herpesvirus vectors and adeno-associated virus vectors, etc. See, also, US patent 6,534,261; 6,607,882; 6,824,978; 6,933,113;
    6,979,539; 7,013,219; and 7,163,824, incorporated by reference here in their entirety. In addition, it is evident that any of these vectors can include one or more ZFN coding sequences. Thus, when one or more pairs of ZFNs are introduced into the cell, the ZFNs can be carried on the same vector in different vectors. When multiple vectors are used, each vector can include a coding sequence of one or more |
    NS | '31/39 ZFNs.
    Conventional viral and non-viral gene transfer methods can be used to introduce nucleic acids that encode projected ZFPs into cells. Said methods can also be used to deliver nucleic acids encoding ZFPs to cells in vitro. In certain embodiments, nucleic acids encoding ZFPs are administered for in vivo or ex vivo uses.
    Non-viral vector delivery systems include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoli- posomes, polycation or lipid conjugates: nucleic acid, naked DNA,: artificial virions, and DNA agent-designed absorption. Sonoporation,. using, for example, the 2000 Sonitron system (Rich-Mar) can also be used for the release of nucleic acids. Viral vector delivery systems include DNA and RNA viruses, which have episomal or integrated genomes after release to the cell. Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus Therapeutics Inc, (see, for example, US 6008336). Lipofection is described for example, US 5,049,386, US 4,946,787; and US 4,897,355) and lipofection reagents are sold co- | commercially (for example, Transfect ”“ and Lipofectint ”). Cationic and neutral lipids that are suitable for polynucleotide receptor recognition lipofection include those of Felgner, WO 91/17424, WO 91/16024. The release can be to target cells (ex vivo administration) or tissues (in vivo administration). The preparation of lipid complexes: nucleic acid, including liposomes targeted as immunolipid complexes, is well known to a person skilled in the art (see, for example, Crystal, Science 270: 404-410 (1995); Blaese et al., Cancer Gene Ther. 2: 291-297 (1995); Behr et al., Bioconjugate Chem. 5: 382-389 (1994); Remy et al., Bio-conjugate Chem. 5: 647-654 (1994); Gao et al., Gene Therapy 2: 710-722 (1995); Ahmad et al, Cancer Res. 52: 4817-4820 (1992); US Patent
    4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728,
    '32/39
    4,774,085, 4,837,028, and 4,946,787).
    Additional delivery methods include the use of nucleic acid packaging to be delivered in En-GenelC delivery vehicles (EDVs). These EDVs are specifically released to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the surface of the target cell, and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see MacDiarmid et al (2009) Nature Biotechnology vol. 27 (7), p.643).
    : As mentioned above, the revealed methods and compositions. can be used in any type of cell. Offspring, variants and derivatives of animal cells can also be used. Applications The revealed methods and compositions can be used for genomic editing of any Rosa gene or genes. In certain applications, methods and compositions can be used to inactivate Rosa genomic sequences. In other applications, the methods and compositions allow for the generation of random mutations, including the generation of new allelic forms of genes with different expression compared to unpublished genes or integration of humanized genes, which allows the generation of animal models. In other applications, methods and compositions can be used to create random mutations at defined gene positions, which allow the identification or selection of animals leading to new allelic forms of those genes. In other applications, the methods and compositions allow for targeted integration of an exogenous (donor) sequence into any selected area of the genome, for example, a mouse or rat Rosa gene. Regulatory sequences (for example, promoters) could be integrated in a targeted manner at a site of interest. "Integration" means both physical insertion | (for example, in the genome of a host cell) when, in addition, integration by donor sequence copy into the genome of the host cell
    ] 33/39 through nucleic acid replication processes. Donor sequences can also include nucleic acids such as ShRNAs, miRNAs, etc. These small nucleic acid donors can be used to study their effects on the genes of interest within the genome. Additional sequences that interest us may be human genes that encode proteins relevant to disease models. Non-limiting examples of said genes include Human factor VIII and Human factor IX. Thus, insertion of these genes into the Rosa locus may allow the researcher to investigate these proteins in greater detail in vivo. Genomic editing (for example, inactivation, integration, and / or targeted or random mutation) of an ani- gene. it can barely be achieved, for example, by a simple cleavage event, b by cleavage followed by non-homologous end joint, by cleavage followed by homology-directed repair mechanisms, by cleavage followed by physical integration of a donor sequence, by cleavage at two sites per joint as well as to delete the sequence between the two cleavage sites, by directed recombination of a codon region of incorrect or nonsense sense, by directed recombination of an irrelevant sequence (that is, a sequence "stuffer") in the gene or its regulatory region, in order to disrupt the gene or regulatory region, or by directed recombination of a splice acceptor sequence in an intron to generate mis-splicing of the transcript. See, US patent publication 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International publication WO 07/014275, the disclosures of which are incorporated by reference in their entirety for all purposes.
    There are a variety of applications for ZFN-mediated genomic editing of a Rosa gene. The methods and compositions described here allow the generation of models of human diseases. For example, editing the p53 gene allows the generation of a "rat cancer" that provides an animal model for studying cancer and testing cancer therapies.
    EXAMPLES Example 1: Construction of restriction fragment length polymorphism donor nucleic acid (RFLP) for direct integration
    Ú 34/39 targeted at the rRosa26 nucleic acid region of the rat genome.
    The plasmids were further constructed to integrate Notl and Pmel RFLP sites in the rRosa26 region of the rat genome.
    The design and construction of the plasmid was as described above.
    The PCR primer pairs used to amplify the rRosa26 region of homology are described in Table 1. [Name [continued =: - 'Zinc finger designs targeting target sites in Rosa26 are shown in Tables 2 and 3. Nucleotides at the destination site are contacted by ZFP recognition propellers are indicated in letters | 10 capital letters; uncontacted nucleotides indicated in lower case. | Table 2: Pink finger designs 26 of rat Fo EEE ES AND ES) 188521 (SEQ IDj (SEQ IDÍ (SEA IDÍ (SEQ ID | (SEQ ID | NA tar) NO: 38) NO: 39) NO: 40) NO : 41) NO: 42) Er EEN EEE 891a1 (SEQ ID / (SEQ IDÍ (SEQ IDj (SEQ ID | (SEA ID | NA tear 1) NO: 43) NO: 44) NO: 45) NO: 46) NO : 47)
    Saz6inton. | RSDHLSE - | RSAMLAR | RSDHLST | QNAHRIT | RSAVLSE 188791 (EQ IDÍ (SEA IDÍ / SEA IDÍ (SEA IDÍ (SEA DINA ar 2) NO: 48) NO: 49) NO: 50) NO: 51) - | NO: 52) Sap6intron- QSGDLTR | TSGSLTR | RSANLTR | RSDHLTK | NSDHLSR B94a1 (SER ID | (SEQR ID | (SEQ ID | (SEQ ID | (SEA DINA (par 2) NO: 17) NO: 18) NO: 42) NO: 45) - | NO: 46)
    Sx6intron. | RSANLTR | QSGDLTR | OQSGDLTR | RSANLAR | RSDNLRE 194121 (SEQ IDÍ (SEQ IDÍ (SEQR ID | (SEA IDÍ (SEA DINA NO: 42) NO: 17 NO: 17 NO: NO: 54 tear 3))) 53))
    Sap6iínton. | RSDHLST | DNRORIK | RSDTLSE | QSSHLAR | QNAHRKT 947a1 (SER IDÍ (SEQ IDj (SEQ ID | (SEA ID | (SEA DINA ar 3) NO: 50) NO: 55) NO: 56) NO: 57) NO: 22)
    Sap6inton. | ASGDLTR | QSGDLTR | RSDONLTR | RSDNLSE | QNAHRKT 194491 (SEQ ID | j (SEQA iDj (SEA iD | (SEA ID | (Sea iID | NA NO1 NO: 1 NO: 58 NO: 21 NO: 22))
    (ar 4) 7 7)))
    If DRSDLSR | RSDHLST | DNRDRIK | RSDTLSE | QSSHLAR sa26intron-
    95021 (SEQ IDj (SEA IDi (sea 1IDÍ (GSEA IDÍ (SEA DINA
    Gar 4) NO: 38) NO: 50) NO: 55) NO: 56) - | NO: 57)
    ro- TSSTR saz6intron- | OSGDLTR | RSDNLTR | RSDNLSE | QNAHRKT | RSDHLSE | KT rn51a1 (SEQ 1D | (SEQ ID | (SEQ ID | (SEQ ID | (SEQ ID | (SEQ
    (pair 5) NO: 17) NO: 58) NO: 21) NO: 22) - | NO48) ID
    NO: 59)
    SoGinton. | TSGNLTR | QSGNLAR | RSDALSV | DSSHRTR | RSDVLSE
    95821 (EQ ID) (tsEa Diksea iDÍ (SEA IDikSEa ID | NA NO: 60) NO: 61) NO: 62) NO: 63) NO: 64)
    (pair 5)
    Sap6ínton. | RSONLSE | QNAHRKT | RSDHLSE | TSSTRKT | TSGHLSR r954a1 (SEC iD | (sea Diksea IDiçsea iwDi (SsEa DINA NO: 21) NO: 22) NO: 48) NO: 59) NO: 40)
    (pair 6)
    so TSGNLTR | osGnLAR | RsDALSV | DSSHRTR sa26intron-
    961a1 (SEQ IDÍ (SEA ID / (SEA ID / (SEA IDÍINA IN
    2:: NO:
    air 6) NO: 60) NO: 61) NO: 62) 10:63)
    So ORSNLVR | RSDHLTA | OQSGHLOR | DRSHLAR sa26 intron-
    198321 sGEQ iDi (ksEa iDl (sea iD | (sea iD | NA NA NO: 65) NO: 66) NO: 67) NO: 68)
    (pair 7)
    ro- RSDVLSE [ORNHRTT | TKRSLE - | TSSNLSR | RSDDLSK | DNRD sa26íntron- | (SEQ ID | (SEQ ID | (SEQ ID | (SEQ ID | (SEQ ID | RIK
    989a1 NO: 64) NO: 69) NO: 70) NO: 71) NO: 25) (SEQ
    '36/39 The loss If RSDHLSA | QSGHLSR | RSDHLSR | QNDNRIK | ASGNLAR sa26íntron- r989a1 (SEG IDj (SEQ IDj (SEQ IDj (SEQ ID | (SEA DINA NO: 72) NO: 24) NO: 47) NO: 73) NO: 61) (par 8) ro- TSSNL sa26intron- Í NNRDLIN | TSSNLSR | RSDVLSE | ORNHRTT | TKRSLIE SR 996a1 (SEQ ID | I (SEQ ID | J (SEQ ID | (SEQ ID | (SEQ 1D | (SEQ (par 8) NO: 74) NO: 71) NO: 64) NO: 69) NO: 70 ) D NO: 71) Table 3: Rat pink26 target sites - [Nomezelh - - [next - | r rosa26íntron-r885a1 ctGAGAAGGGTGCGGCCttttetecgee pair 1 SEQ ID NO: 75 rosa26íntron-891a1 acGGGGGAGGGGAGTGTtgcaatacctt pair 1 SEQ ID NO: 76 rosa26íntron-r887a1 tcoTGAGAAGGGTGCGGccttttetecg pair 2 SEQ ID NO: 77 'rosa26íntron-894a1 ggGGAGGGGAGtGTTGCAatacctttct pair 2 SEQ ID NO: 78 rosa26íntron-r941a1 gacCAGGAGGCAGCAGAGaactcccagaa pair 3 'SEQ ID NO: 79 rosa26íntron 947a1 teTGAGGACCGCCCTGGgcectagaagat-pair 3' SEQ ID NO: 80 rosa26íntron 4-r944a1 gaAGACAGGAGGCAGCAgagaactccca pair SEQ ID NO: 81 rosa26íntron-4 950a1 gaGGACCGCCCTGGGCCtggaagattce pair SEQ ID NO: 82 rosa26íntron-r951a1 gtcCCTCAGaAGACAGGAGGCAgcagaga pair SEQ ID NO 5 : 83. | rosa26íntron-958a1 cecTGGGCCTGGAAGATtecettecece par 5 SEQ ID NO: 84 rosa26íntron-r954a1 geGGTCCTCAGaAGACAGgaggcageag |
    S 37/39 | NomezEN | seguêncizamo = | [ea [een | par 6 SEQ ID NO: 86: par 7 SEQ ID NO: 87 'par 7 SEQ ID NO: 88. par 8 SEQ ID NO: 89, par 8 SEQ ID NO: 90. | C6 cells from rats were transfected with GFP control or each of the 8 pairs of ZFNs. DNA was prepared from cells one day after transfection. ZFN cleavage was analyzed with the Surveuror "" M nuclease as described, for example, in US patent publication Nos. 20080015164; 20080131962 and 20080159996, using the amplified products with respective primers. The results are shown in the figure
    1. Arrows indicate that cleavage was found only in samples containing ZFN pairs, but was not found in control samples in which cells were transfected with GFP-specific ZFNs. Example 2: Zinc Finger Nucleases Specific for Mouse Rosa26 Locus Zinc finger designs targeted at mouse Rosa26 target sites are shown in Tables 4 and 5. Nucleotides at the destination site are contacted by ZFP recognition propellers are indicated capitalized letters; uncontacted nucleotides indicated in lower case.
    S 38/39 Table 4: Rosa26 zinc finger designs of mouse Ir Pr R (SEQ | (SEDQ ID | (SEQ IDJ (SEQ IDI (SEQ ID | (SEQ ID ID NO: 17) | NO: 18) NO : 19) NO: 20) NO: 21) NO: 22) 18473 | DRSART | OSGHLSR | RSDDLSK | RNDHRKN R (SEQ | (SEQ ID | (SEQ ID | (SEQ ID | N / AN / A CESEeS SE and 25096 go TSGSLTR | OSGHLAR | OSSDLTR | RSDNLSE | QNAHRKT Gea 19 | Gão, te 6ão, tome, Demo, Pes NO: 27) '': ': - Table 5: Rosa26 mouse target sites with Eomezen | sequavo = | [25066 - - | SIAGAMAGACTGGAGTTGCAgatcacga (SEQ ID NO: 30) | Analysis of Cel-I was conducted as described above for ZFN pairs 18473/18477 and 18473/25096 and the NHEJ percentage was observed as follows: 26.5% NHEJ using pair ZFN 18477/18473 and 35.70% NHEJ with pair ZFN 18473/25096 Example 3: Targeted integration of a donor polynucleotide at Rosa26 locus of the mouse genome Rosa Donors were constructed by cloning PCR products using the following oligonucleotides: for 527 bp arms, the oligonucleotides used for PCR were 5'-ggc tcg agt gag tca tac gac tte taa gat cag 9g-3 '(SEQ ID NO: 31); for left arm donors 413 bp, 5'-ggc teg agt ttt gat aag gct gca gaa 9g-3' (SEQ ID NO: 32) in conjunction with the primerreverse 5'-ctg aat tcg aat ggg cgg gag tet tcet ggg ca-3 '(SEQ ID NO: 33). For 640 bp right arms, the oligonucleotides used for PCR were 5'-cca agc ttg gag gta ggt gagg gta agg-3 '(SEQ ID NO: 34); for 200 bp arms, 5'-cca agc tta gtc gct ctg agt tat tat c-3 '(SEQ ID NO: 35); for arms 100 bp, 5'-cca agc ttt ctg gga gtt ctc tac tao c-3 '(SEQ ID NO: 36) in conjunction with the 5'-cat tcg reverse primer aat tca gaa aga ctg gag ttg cag
    '39/39 atc-3' (SEQ ID NO: 37). Individual arm amplicons were joined by fusing the PCR and cloned to produce donors with different homology arms. Neuro2a cells (200,000) were cotransfected with 400 ng each of SBS 18473 and 18477 together with 2 µg of the donor indicated in the - SF solution using the high-efficiency Amaxa-Shuttle Neuro2a protocol.
    Genomic DNA was collected 72 hours after transfection and 100 ng used for PCR with 5'-cccagctacagcctegattt-3 ', 5'-cacaaatggcgtattttagt- 3' and 5 / Ci of both 32P-dATP and 32P-dCTP per sample in a temperature annealing rate of 68ºC with an extension of two minutes at 72ºC for 28 cycles. After purifying the G-50 column, 10 μl of each 50 μl of reaction was: digested at 37ºC for two hours and loaded on 10% polyacrylamide ice.
    As shown in figure 2, the donor nucleotides were inserted into the Rosa locus at the indicated frequency.
    All patents, patents and publications mentioned herein are incorporated by reference in their entirety.
    Although revelation has been provided in some detail as an illustration and example for the sake of clarity of understanding, it will be evident to those skilled in the art that various changes and modifications can be practiced without departing from the spirit and spirit. scope of disclosure. Therefore, the preceding descriptions and examples should not be interpreted as limiting.
    权利要求:
    Claims (24)
    [1]
    1. Fusion protein, which comprises a nuclease and a projected zinc finger domain, where the projected zinc finger domain binds to a target site specified in any of SEQ ID NOS: 28-30 and 75-90 . |
    [2]
    A fusion protein according to claim 1, wherein the nuclease comprises a cleavage domain or cleavage half-domain.
    [3]
    Fusion protein according to claim 1 or 2, in. 10 that the nuclease comprises a Type IIS restriction endonuclease cleavage domain or half-domain.
    [4]
    ”4. Fusion protein according to claim 3, wherein the cleavage domain or cleavage half-domain is naturally occurring or engineered.
    [5]
    Polynucleotide, which encodes a fusion protein as defined in any one of claims 1 to 4.
    [6]
    6. Cell, which comprises a fusion protein as defined | in any one of claims 1 to 4, or a polynucleotide as defined in claim 5.
    [7]
    Cell, according to claim 6, wherein the cell is an embryonic cell.
    [8]
    8. Composition, which comprises a fusion protein as | defined in any one of claims 1 to 4, or a polynucleotide as defined in claim 5, and a pharmaceutically acceptable excipient | 25 table.
    [9]
    | 9. Method for cleaving one or more Rosa genes in a cell, the method comprising: | introducing into the cell one or more fusion proteins as defined in any one of claims 1 to 4, or one or more polynucleotides as defined in claim 5, in the cell, so that the one or more Rosa genes are cleaved.
    [10]
    10. Method for introducing a polynucleotide sequence |
    '213 exogenous in the genome of a cell, the method comprising: cleaving one or more Rosa genes as defined in claim ge | contacting the cell with an exogenous polynucleotide sequence in which the cleavage of one or more genes stimulates integration of the exogenous polynucleotide sequence into the genome by homologous recombination.
    [11]
    11. The method of claim 10, wherein the exogenous polynucleotide sequence is physically in the genome.
    [12]
    : 12. The method of claim 11, wherein the exogenous polynucleotide sequence is integrated into the genome by means of nucleic acid replication processes.
    [13]
    13. The method of claim 11, wherein the exogenous polynucleotide sequence is integrated into the genome by means of targeted integration dependent on non-homology.
    [14]
    14. Method for modifying a sequence of Rosa genes in | cell genome, the method comprising cleaving one or more Rosa genes as defined in claim 9 wherein (i) a first ZFN cleaves at a first cleavage site and a second ZFN cleaves at a second cleavage site; (ii) the Rosa gene sequence is located between the first cleavage site and the second cleavage site; (iii) cleavage of the first and second cleavage sites results in a modification of the gene sequence by non-homologous end joining or homology-directed repair.
    [15]
    A method according to claim 14, wherein the modification comprises a deletion.
    [16]
    16. The method of claim 15, wherein the modification comprises insertion of an exogenous sequence.
    [17]
    17. Method for generating a transgenic animal, the method that
    | NM S 33 comprises: modifying a sequence of Rosa genes in an embryonic cell as defined in any one of claims 14 to 16; and allow the embryo to grow into an animal.
    [18]
    18. The method of claim 17, wherein the modification | cation comprises one or more random mutations at defined positions. | |
    [19]
    19. The method of claim 17, wherein the modification! cation comprises insertion of a humanized gene.
    [20]
    20. The method of claim 19, wherein the humanized gene is associated with drug metabolism. :
    [21]
    21. The method of any one of claims 17 xr to 20, wherein the animal is a sexually mature animal and the modified gene sequences are present in at least a portion of gametes of the sexually mature animal.
    [22]
    22. Method for creating one or more hereditary mutant alleles in at least one Rosa locus of interest, the method comprising generating a transgenic animal as defined in any one | claims 17 to 21, wherein the embryo is elevated to sexual maturity to allow the sexually mature animal to produce offspring; wherein at least some of the descendants comprise the mutant alleles.
    [23]
    23. Kit, which comprises a fusion protein as defined | in any one of claims 1 to 4, or a polynucleotide as defined in claim 5.
    [24]
    24. Kit according to claim 23, which further comprises additional components selected from the group consisting of one or more exogenous sequences, instructions for use and combinations thereof. |
    ! : O.
    À e e o - +, o) SE | and. à o -: o Te -— = 3 o s TA N lg De º Ss o. ".. It is.
    H | 8 2: m | É | º, in Si Ss o: TE JD | am! IT IS. x o - | O! CNE Í and <e. sec ME:: ERR bs | ! "Am. À | se 8 8 ww oO Ex
    | | + | |
    Í | > 1 212! | | | | if | and the 1 '1 1 E to the east. E = ts | “Wã Fo º 2 ns * ms:> NM 5 m and be wu -1SERN at - Mo E E F eo; =. À io bo: o. rm “TORA Sb = | -seR 3d -: a s u. s rm r 4 ij »EFE À à" E + rt. OS BE: el mr À r Ha Ho xD A so &. = = - à E = the 2nd EE 1a SEO "Bs $ i:: - do S NM E O Ss o Ss ecE = Oo o S EX oo =
    X
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012027532A2|2020-10-13|genome editing of a pink locus using zinc finger nucleases.
    US9631187B2|2017-04-25|Methods and compositions for gene correction
    KR101803737B1|2017-12-01|Genome editing in rats using zinc-finger nucleases
    AU2012328682B2|2017-09-21|Methods and compositions for modification of the HPRT locus
    US20090203140A1|2009-08-13|Genomic editing in zebrafish using zinc finger nucleases
    US9161995B2|2015-10-20|Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator | gene
    同族专利:
    公开号 | 公开日
    EP2563918B1|2016-11-23|
    EP2563918A1|2013-03-06|
    US20120017290A1|2012-01-19|
    JP2013526857A|2013-06-27|
    US9567573B2|2017-02-14|
    US20110265198A1|2011-10-27|
    SG185367A1|2012-12-28|
    JP5952263B2|2016-07-13|
    JP2016138104A|2016-08-04|
    CN102939377A|2013-02-20|
    KR101880536B1|2018-07-23|
    CA2796600C|2019-08-13|
    KR20130073879A|2013-07-03|
    US8771985B2|2014-07-08|
    CN102939377B|2016-06-08|
    WO2011139336A1|2011-11-10|
    WO2011139335A1|2011-11-10|
    EP2563918A4|2013-10-16|
    CA2796600A1|2011-11-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5356802A|1992-04-03|1994-10-18|The Johns Hopkins University|Functional domains in flavobacterium okeanokoites restriction endonuclease|
    US5436150A|1992-04-03|1995-07-25|The Johns Hopkins University|Functional domains in flavobacterium okeanokoities restriction endonuclease|
    US5487994A|1992-04-03|1996-01-30|The Johns Hopkins University|Insertion and deletion mutants of FokI restriction endonuclease|
    US6140466A|1994-01-18|2000-10-31|The Scripps Research Institute|Zinc finger protein derivatives and methods therefor|
    US6242568B1|1994-01-18|2001-06-05|The Scripps Research Institute|Zinc finger protein derivatives and methods therefor|
    JP4012243B2|1994-01-18|2007-11-21|ザスクリップスリサーチインスティチュート|Zinc finger protein derivatives and methods therefor|
    AU698152B2|1994-08-20|1998-10-22|Gendaq Limited|Improvements in or relating to binding proteins for recognition of DNA|
    US5789538A|1995-02-03|1998-08-04|Massachusetts Institute Of Technology|Zinc finger proteins with high affinity new DNA binding specificities|
    US5925523A|1996-08-23|1999-07-20|President & Fellows Of Harvard College|Intraction trap assay, reagents and uses thereof|
    GB2338237B|1997-02-18|2001-02-28|Actinova Ltd|In vitro peptide or protein expression library|
    GB9703369D0|1997-02-18|1997-04-09|Lindqvist Bjorn H|Process|
    GB9710809D0|1997-05-23|1997-07-23|Medical Res Council|Nucleic acid binding proteins|
    GB9710807D0|1997-05-23|1997-07-23|Medical Res Council|Nucleic acid binding proteins|
    US6410248B1|1998-01-30|2002-06-25|Massachusetts Institute Of Technology|General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites|
    WO1999045132A1|1998-03-02|1999-09-10|Massachusetts Institute Of Technology|Poly zinc finger proteins with improved linkers|
    US6140081A|1998-10-16|2000-10-31|The Scripps Research Institute|Zinc finger binding domains for GNN|
    GB9824544D0|1998-11-09|1999-01-06|Medical Res Council|Screening system|
    US7013219B2|1999-01-12|2006-03-14|Sangamo Biosciences, Inc.|Regulation of endogenous gene expression in cells using zinc finger proteins|
    US6453242B1|1999-01-12|2002-09-17|Sangamo Biosciences, Inc.|Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites|
    US6534261B1|1999-01-12|2003-03-18|Sangamo Biosciences, Inc.|Regulation of endogenous gene expression in cells using zinc finger proteins|
    US6599692B1|1999-09-14|2003-07-29|Sangamo Bioscience, Inc.|Functional genomics using zinc finger proteins|
    AT309536T|1999-12-06|2005-11-15|Sangamo Biosciences Inc|METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS|
    WO2001059450A2|2000-02-08|2001-08-16|Sangamo Biosciences, Inc.|Cells expressing zinc finger protein for drug discovery|
    US20020061512A1|2000-02-18|2002-05-23|Kim Jin-Soo|Zinc finger domains and methods of identifying same|
    US20030044787A1|2000-05-16|2003-03-06|Joung J. Keith|Methods and compositions for interaction trap assays|
    JP2002060786A|2000-08-23|2002-02-26|Kao Corp|Germicidal stainproofing agent for hard surface|
    US6794136B1|2000-11-20|2004-09-21|Sangamo Biosciences, Inc.|Iterative optimization in the design of binding proteins|
    GB0108491D0|2001-04-04|2001-05-23|Gendaq Ltd|Engineering zinc fingers|
    EP1421177A4|2001-08-20|2006-06-07|Scripps Research Inst|Zinc finger binding domains for cnn|
    CA2474486C|2002-01-23|2013-05-14|The University Of Utah Research Foundation|Targeted chromosomal mutagenesis using zinc finger nucleases|
    US20030232410A1|2002-03-21|2003-12-18|Monika Liljedahl|Methods and compositions for using zinc finger endonucleases to enhance homologous recombination|
    CA2497913C|2002-09-05|2014-06-03|California Institute Of Technology|Use of chimeric nucleases to stimulate gene targeting|
    EP1445320A1|2003-02-05|2004-08-11|ARTEMIS Pharmaceuticals GmbH|Automated gene-targeting using non-toxic detectable markers|
    US8409861B2|2003-08-08|2013-04-02|Sangamo Biosciences, Inc.|Targeted deletion of cellular DNA sequences|
    US7972854B2|2004-02-05|2011-07-05|Sangamo Biosciences, Inc.|Methods and compositions for targeted cleavage and recombination|
    US7888121B2|2003-08-08|2011-02-15|Sangamo Biosciences, Inc.|Methods and compositions for targeted cleavage and recombination|
    JP4555292B2|2003-08-08|2010-09-29|サンガモバイオサイエンシズインコーポレイテッド|Methods and compositions for targeted cleavage and recombination|
    CA2579677A1|2004-09-16|2006-03-30|Sangamo Biosciences, Inc.|Compositions and methods for protein production|
    JP2009502170A|2005-07-26|2009-01-29|サンガモバイオサイエンシズインコーポレイテッド|Targeted integration and expression of foreign nucleic acid sequences|
    US20080015164A1|2006-05-19|2008-01-17|Sangamo Biosciences, Inc.|Methods and compositions for inactivation of dihydrofolate reductase|
    CA2651494C|2006-05-25|2015-09-29|Sangamo Biosciences, Inc.|Engineered cleavage half-domains|
    AT536371T|2006-05-25|2011-12-15|Sangamo Biosciences Inc|PROCESS AND COMPOSITIONS FOR GENERIC ACTIVATION|
    CN105296527B|2006-08-11|2020-11-27|陶氏益农公司|Zinc finger nuclease-mediated homologous recombination|
    US8110379B2|2007-04-26|2012-02-07|Sangamo Biosciences, Inc.|Targeted integration into the PPP1R12C locus|
    AU2009260888B2|2008-05-28|2014-09-11|Sangamo Therapeutics, Inc.|Compositions for linking DNA-binding domains and cleavage domains|
    KR101759586B1|2008-08-22|2017-07-19|상가모 테라퓨틱스, 인코포레이티드|Methods and compositions for targeted single-stranded cleavage and targeted integration|
    EP2206723A1|2009-01-12|2010-07-14|Bonas, Ulla|Modular DNA-binding domains|
    WO2011051390A1|2009-10-28|2011-05-05|Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt |Homologous recombination in the oocyte|
    JP2013513389A|2009-12-10|2013-04-22|リージェンツオブザユニバーシティオブミネソタ|DNA modification mediated by TAL effectors|
    WO2011090804A1|2010-01-22|2011-07-28|Dow Agrosciences Llc|Targeted genomic alteration|
    EP3594333A1|2010-02-08|2020-01-15|Sangamo Therapeutics, Inc.|Engineered cleavage half-domains|
    KR101953237B1|2010-05-17|2019-02-28|상가모 테라퓨틱스, 인코포레이티드|Novel dna-binding proteins and uses thereof|EP2206723A1|2009-01-12|2010-07-14|Bonas, Ulla|Modular DNA-binding domains|
    US20110239315A1|2009-01-12|2011-09-29|Ulla Bonas|Modular dna-binding domains and methods of use|
    JP2013513389A|2009-12-10|2013-04-22|リージェンツオブザユニバーシティオブミネソタ|DNA modification mediated by TAL effectors|
    KR101953237B1|2010-05-17|2019-02-28|상가모 테라퓨틱스, 인코포레이티드|Novel dna-binding proteins and uses thereof|
    WO2013086008A1|2011-12-05|2013-06-13|Factor Bioscience Inc.|Methods and products for transfecting cells|
    WO2013102289A1|2012-01-04|2013-07-11|清华大学|Specific binding and targeting method for dna-rna heteroduplex|
    WO2013102290A1|2012-01-04|2013-07-11|清华大学|Method for specifically recognizing dna containing 5-methylated cytosine|
    DK3415158T3|2012-03-15|2021-01-11|Cellectis|REPEAT-VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES|
    US10648001B2|2012-07-11|2020-05-12|Sangamo Therapeutics, Inc.|Method of treating mucopolysaccharidosis type I or II|
    US10883119B2|2012-07-11|2021-01-05|Sangamo Therapeutics, Inc.|Methods and compositions for delivery of biologics|
    DK3196301T3|2012-07-11|2019-01-14|Sangamo Therapeutics Inc|METHODS AND COMPOSITIONS FOR TREATING MONOGENIC DISEASES|
    CA2892448A1|2012-12-05|2014-06-12|Sangamo Biosciences, Inc.|Methods and compositions for regulation of metabolic disorders|
    KR20150105956A|2012-12-12|2015-09-18|더 브로드 인스티튜트, 인코퍼레이티드|Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications|
    WO2014093701A1|2012-12-12|2014-06-19|The Broad Institute, Inc.|Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof|
    SG11201510327TA|2013-06-17|2016-01-28|Broad Inst Inc|Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells|
    EP3597755A1|2013-06-17|2020-01-22|The Broad Institute, Inc.|Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components|
    EP3825406A1|2013-06-17|2021-05-26|The Broad Institute Inc.|Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy|
    CN105120656A|2012-12-21|2015-12-02|塞尔克蒂斯股份有限公司|Potatoes with reduced cold-induced sweetening|
    EP2958996B1|2013-02-25|2019-10-16|Sangamo Therapeutics, Inc.|Methods and compositions for enhancing nuclease-mediated gene disruption|
    US10113162B2|2013-03-15|2018-10-30|Cellectis|Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes|
    EP2975942B1|2013-03-21|2018-08-08|Sangamo Therapeutics, Inc.|Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases|
    CA2910427A1|2013-05-10|2014-11-13|Sangamo Biosciences, Inc.|Delivery methods and compositions for nuclease-mediated genome engineering|
    US9873894B2|2013-05-15|2018-01-23|Sangamo Therapeutics, Inc.|Methods and compositions for treatment of a genetic condition|
    SG11201510297QA|2013-06-19|2016-01-28|Sigma Aldrich Co Llc|Targeted integration|
    EP3039136B8|2013-08-28|2020-12-16|Sangamo Therapeutics, Inc.|Compositions for linking dna-binding domains and cleavage domains|
    WO2015057976A1|2013-10-17|2015-04-23|Sangamo Biosciences, Inc.|Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells|
    WO2015057980A1|2013-10-17|2015-04-23|Sangamo Biosciences, Inc.|Delivery methods and compositions for nuclease-mediated genome engineering|
    EP3068905A4|2013-11-11|2017-07-05|Sangamo BioSciences, Inc.|Methods and compositions for treating huntington's disease|
    RS58671B1|2013-11-13|2019-06-28|Childrens Medical Center|Nuclease-mediated regulation of gene expression|
    JP6535684B2|2013-12-09|2019-06-26|サンガモ セラピューティクス， インコーポレイテッド|Methods and compositions for genome manipulation|
    EP3080271B1|2013-12-12|2020-02-12|The Broad Institute, Inc.|Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems|
    EP3470089A1|2013-12-12|2019-04-17|The Broad Institute Inc.|Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components|
    CN111269902A|2013-12-12|2020-06-12|布罗德研究所有限公司|Delivery and use of CRISPR-CAS systems and compositions|
    CN106030310B|2013-12-13|2019-01-04|通用医疗公司|Soluble high-molecular amountTAU type and its application|
    WO2015117081A2|2014-02-03|2015-08-06|Sangamo Biosciences, Inc.|Methods and compositions for treatment of a beta thalessemia|
    EP3110454B1|2014-02-24|2020-11-18|Sangamo Therapeutics, Inc.|Methods and compositions for nuclease-mediated targeted integration|
    ES2879373T3|2014-03-18|2021-11-22|Sangamo Therapeutics Inc|Methods and compositions for the regulation of zinc finger protein expression|
    WO2015164748A1|2014-04-24|2015-10-29|Sangamo Biosciences, Inc.|Engineered transcription activator like effectorproteins|
    MX2016014565A|2014-05-08|2017-05-23|Sangamo Biosciences Inc|Methods and compositions for treating huntington's disease.|
    CA2947622A1|2014-05-13|2015-11-19|Sangamo Biosciences, Inc.|Methods and compositions for prevention or treatment of a disease|
    EP3151846A4|2014-06-05|2017-12-27|Sangamo BioSciences, Inc.|Methods and compositions for nuclease design|
    EP3158072B1|2014-06-20|2021-01-13|Cellectis|Potatoes with reduced granule-bound starch synthase|
    WO2016014837A1|2014-07-25|2016-01-28|Sangamo Biosciences, Inc.|Gene editing for hiv gene therapy|
    WO2016014794A1|2014-07-25|2016-01-28|Sangamo Biosciences, Inc.|Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells|
    WO2016019144A2|2014-07-30|2016-02-04|Sangamo Biosciences, Inc.|Gene correction of scid-related genes in hematopoietic stem and progenitor cells|
    SI3194570T1|2014-09-16|2022-01-31|Sangamo Therapeutics, Inc.|Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells|
    WO2016049163A2|2014-09-24|2016-03-31|The Broad Institute Inc.|Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder|
    WO2016049251A1|2014-09-24|2016-03-31|The Broad Institute Inc.|Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes|
    EP3212788A2|2014-10-27|2017-09-06|The Broad Institute, Inc.|Compositions, methods and use of synthetic lethal screening|
    WO2016094874A1|2014-12-12|2016-06-16|The Broad Institute Inc.|Escorted and functionalized guides for crispr-cas systems|
    EP3230452A1|2014-12-12|2017-10-18|The Broad Institute Inc.|Dead guides for crispr transcription factors|
    WO2016094867A1|2014-12-12|2016-06-16|The Broad Institute Inc.|Protected guide rnas |
    US10889834B2|2014-12-15|2021-01-12|Sangamo Therapeutics, Inc.|Methods and compositions for enhancing targeted transgene integration|
    EP3702456A1|2014-12-24|2020-09-02|The Broad Institute, Inc.|Crispr having or associated with destabilization domains|
    WO2016108926A1|2014-12-30|2016-07-07|The Broad Institute Inc.|Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis|
    US20180002379A1|2015-01-21|2018-01-04|Sangamo Therapeutics, Inc.|Methods and compositions for identification of highly specific nucleases|
    US10179918B2|2015-05-07|2019-01-15|Sangamo Therapeutics, Inc.|Methods and compositions for increasing transgene activity|
    EP3294866A4|2015-05-12|2018-12-05|Sangamo Therapeutics, Inc.|Nuclease-mediated regulation of gene expression|
    WO2016205728A1|2015-06-17|2016-12-22|Massachusetts Institute Of Technology|Crispr mediated recording of cellular events|
    US9957501B2|2015-06-18|2018-05-01|Sangamo Therapeutics, Inc.|Nuclease-mediated regulation of gene expression|
    RU2018101732A3|2015-06-18|2020-01-31|
    EP3436575A1|2015-06-18|2019-02-06|The Broad Institute Inc.|Novel crispr enzymes and systems|
    EP3129393B1|2015-06-18|2021-08-04|The Broad Institute Inc.|Crispr enzyme mutations reducing off-target effects|
    US9790490B2|2015-06-18|2017-10-17|The Broad Institute Inc.|CRISPR enzymes and systems|
    AU2016291778B2|2015-07-13|2021-05-06|Sangamo Therapeutics, Inc.|Delivery methods and compositions for nuclease-mediated genome engineering|
    US10837024B2|2015-09-17|2020-11-17|Cellectis|Modifying messenger RNA stability in plant transformations|
    EP3352776A4|2015-09-23|2019-03-13|Sangamo Therapeutics, Inc.|Htt repressors and uses thereof|
    WO2017069958A2|2015-10-09|2017-04-27|The Brigham And Women's Hospital, Inc.|Modulation of novel immune checkpoint targets|
    WO2017070605A1|2015-10-22|2017-04-27|The Broad Institute Inc.|Type vi-b crispr enzymes and systems|
    EP3368687B1|2015-10-27|2021-09-29|The Broad Institute, Inc.|Compositions and methods for targeting cancer-specific sequence variations|
    WO2017075451A1|2015-10-28|2017-05-04|The Broad Institute Inc.|Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1|
    EP3368689B1|2015-10-28|2020-06-17|The Broad Institute, Inc.|Composition for modulating immune responses by use of immune cell gene signature|
    WO2017075465A1|2015-10-28|2017-05-04|The Broad Institute Inc.|Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3|
    SG11201803547RA|2015-10-28|2018-05-30|Sangamo Therapeutics Inc|Liver-specific constructs, factor viii expression cassettes and methods of use thereof|
    EP3380622A4|2015-11-23|2019-08-07|Sangamo Therapeutics, Inc.|Methods and compositions for engineering immunity|
    US20190233814A1|2015-12-18|2019-08-01|The Broad Institute, Inc.|Novel crispr enzymes and systems|
    EA201891212A1|2015-12-18|2019-01-31|Сангамо Терапьютикс, Инк.|ADDRESS DISORGANIZATION OF GKGS CELL RECEPTOR|
    CN109152847A|2016-01-15|2019-01-04|桑格摩生物治疗股份有限公司|For treating the method and composition of neurological disease|
    WO2017134601A1|2016-02-02|2017-08-10|Cellectis|Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes|
    AU2016391970A1|2016-02-02|2018-07-26|Sangamo Therapeutics, Inc.|Compositions for linking DNA-binding domains and cleavage domains|
    EP3445856A1|2016-04-19|2019-02-27|The Broad Institute Inc.|Novel crispr enzymes and systems|
    CN109642231A|2016-06-17|2019-04-16|博德研究所|VI type CRISPR ortholog and system|
    US20210222164A1|2016-06-29|2021-07-22|The Broad Institute, Inc.|Crispr-cas systems having destabilization domain|
    WO2018035364A1|2016-08-17|2018-02-22|The Broad Institute Inc.|Product and methods useful for modulating and evaluating immune responses|
    EP3500967A1|2016-08-17|2019-06-26|The Broad Institute, Inc.|Methods for identifying class 2 crispr-cas systems|
    KR20190039530A|2016-08-24|2019-04-12|상가모 테라퓨틱스, 인코포레이티드|Regulation of gene expression using engineered nuclease|
    SG10201913948PA|2016-08-24|2020-03-30|Sangamo Therapeutics Inc|Engineered target specific nucleases|
    US20190262399A1|2016-09-07|2019-08-29|The Broad Institute, Inc.|Compositions and methods for evaluating and modulating immune responses|
    US10960085B2|2016-09-07|2021-03-30|Sangamo Therapeutics, Inc.|Modulation of liver genes|
    WO2018067991A1|2016-10-07|2018-04-12|The Brigham And Women's Hospital, Inc.|Modulation of novel immune checkpoint targets|
    BR112019007210A2|2016-10-20|2019-08-13|Sangamo Therapeutics Inc|Methods and Compositions for the Treatment of Fabry Disease|
    AU2017347928A1|2016-10-31|2019-05-09|Sangamo Therapeutics, Inc.|Gene correction of scid-related genes in hematopoietic stem and progenitor cells|
    EP3551753A4|2016-12-09|2020-10-07|The Broad Institute, Inc.|Crispr effector system based diagnostics|
    JP2020511141A|2017-03-15|2020-04-16|ザ・ブロード・インスティテュート・インコーポレイテッド|Novel Cas13b ortholog CRISPR enzyme and system|
    US11174515B2|2017-03-15|2021-11-16|The Broad Institute, Inc.|CRISPR effector system based diagnostics|
    JP2020516285A|2017-04-12|2020-06-11|ザ・ブロード・インスティテュート・インコーポレイテッド|New VI type CRISPR ortholog and system|
    US11072816B2|2017-05-03|2021-07-27|The Broad Institute, Inc.|Single-cell proteomic assay using aptamers|
    RU2020105343A3|2017-07-31|2021-11-11|
    KR20200032117A|2017-07-31|2020-03-25|리제너론 파마슈티칼스 인코포레이티드|Evaluation of CRISPR / Cas-induced recombination with exogenous donor nucleic acids in vivo|
    JP2020533957A|2017-07-31|2020-11-26|リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ．|CRISPR Reporter Non-Human Animals and Their Use|
    WO2019084552A1|2017-10-27|2019-05-02|The Regents Of The University Of California|Targeted replacement of endogenous t cell receptors|
    BR112020015093A2|2018-01-29|2020-12-08|The Broad Institute, Inc.|DIAGNOSIS BASED ON THE CRISPR EFFECTOR SYSTEM|
    WO2019183123A1|2018-03-19|2019-09-26|Regeneron Pharmaceuticals, Inc.|Transcription modulation in animals using crispr/cas systems|
    JP2021520211A|2018-04-05|2021-08-19|ジュノー セラピューティクス インコーポレイテッド|T cells expressing recombinant receptors, related polynucleotides, and methods|
    KR20210029707A|2018-04-05|2021-03-16|주노 쎄러퓨티크스 인코퍼레이티드|Method for producing cells expressing recombinant receptors and related compositions|
    WO2019210268A2|2018-04-27|2019-10-31|The Broad Institute, Inc.|Sequencing-based proteomics|
    US20210371932A1|2018-06-01|2021-12-02|Massachusetts Institute Of Technology|Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients|
    SG11202012785VA|2018-06-26|2021-01-28|Broad Inst Inc|Crispr double nickase based amplification compositions, systems, and methods|
    SG11202102068TA|2018-07-31|2021-03-30|Broad Inst Inc|Novel crispr enzymes and systems|
    WO2020041387A1|2018-08-20|2020-02-27|The Brigham And Women's Hospital, Inc.|Degradation domain modifications for spatio-temporal control of rna-guided nucleases|
    US20210355522A1|2018-08-20|2021-11-18|The Broad Institute, Inc.|Inhibitors of rna-guided nuclease activity and uses thereof|
    WO2020041380A1|2018-08-20|2020-02-27|The Broad Institute, Inc.|Methods and compositions for optochemical control of crispr-cas9|
    WO2020069029A1|2018-09-26|2020-04-02|Emendobio Inc.|Novel crispr nucleases|
    US20210396756A1|2018-10-03|2021-12-23|The Broad Institute, Inc.|Crispr effector system based diagnostics for hemorrhagic fever detection|
    WO2020077135A1|2018-10-10|2020-04-16|Dana-Farber Cancer Institute, Inc.|Modulating resistance to bcl-2 inhibitors|
    WO2020077236A1|2018-10-12|2020-04-16|The Broad Institute, Inc.|Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues|
    US20210379057A1|2018-10-16|2021-12-09|Massachusetts Institute Of Technology|Nutlin-3a for use in treating a mycobacterium tuberculosis infection|
    TW202028461A|2018-10-18|2020-08-01|美商英特利亞醫療公司|Nucleic acid constructs and methods of use|
    US20220073987A1|2018-11-14|2022-03-10|The Broad Institute, Inc.|Crispr system based droplet diagnostic systems and methods|
    AU2019380590A1|2018-11-14|2021-07-01|Massachusetts Institute Of Technology|Multiplexing highly evolving viral variants with Sherlock detection method|
    WO2020124050A1|2018-12-13|2020-06-18|The Broad Institute, Inc.|Tiled assays using crispr-cas based detection|
    AU2019406778A1|2018-12-17|2021-07-22|Massachusetts Institute Of Technology|Crispr-associated transposase systems and methods of use thereof|
    WO2020163379A1|2019-02-05|2020-08-13|Emendobio Inc.|Crispr compositions and methods for promoting gene editing of ribosomal protein s19gene|
    WO2020163307A1|2019-02-06|2020-08-13|Emendobio Inc.|New engineered high fidelity cas9|
    WO2020186231A2|2019-03-14|2020-09-17|The Broad Institute, Inc.|Crispr effector system based multiplex diagnostics|
    WO2020191102A1|2019-03-18|2020-09-24|The Broad Institute, Inc.|Type vii crispr proteins and systems|
    AU2020256225A1|2019-04-03|2021-09-02|Regeneron Pharmaceuticals, Inc.|Methods and compositions for insertion of antibody coding sequences into a safe harbor locus|
    WO2020223539A1|2019-04-30|2020-11-05|The Broad Institute, Inc.|Methods and compositions for barcoding nucleic acid libraries and cell populations|
    WO2020223571A1|2019-05-01|2020-11-05|Juno Therapeutics, Inc.|Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods|
    AU2020265741A1|2019-05-01|2021-11-25|Editas Medicine, Inc.|Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods|
    WO2020236972A2|2019-05-20|2020-11-26|The Broad Institute, Inc.|Non-class i multi-component nucleic acid targeting systems|
    WO2020243661A1|2019-05-31|2020-12-03|The Broad Institute, Inc.|Methods for treating metabolic disorders by targeting adcy5|
    SG11202111943UA|2019-07-02|2021-11-29|Hutchinson Fred Cancer Res|Recombinant ad35 vectors and related gene therapy improvements|
    WO2021028359A1|2019-08-09|2021-02-18|Sangamo Therapeutics France|Controlled expression of chimeric antigen receptors in t cells|
    WO2021041922A1|2019-08-30|2021-03-04|The Broad Institute, Inc.|Crispr-associated mu transposase systems|
    WO2021046257A1|2019-09-03|2021-03-11|The Broad Institute, Inc.|Crispr effector system based multiplex cancer diagnostics|
    WO2021050974A1|2019-09-12|2021-03-18|The Broad Institute, Inc.|Engineered adeno-associated virus capsids|
    WO2021055874A1|2019-09-20|2021-03-25|The Broad Institute, Inc.|Novel type vi crispr enzymes and systems|
    WO2021055855A1|2019-09-20|2021-03-25|The Broad Institute, Inc.|Compositions and methods for delivering cargo to a target cell|
    WO2021092513A1|2019-11-08|2021-05-14|Regeneron Pharmaceuticals, Inc.|Crispr and aav strategies for x-linked juvenile retinoschisis therapy|
    WO2021108363A1|2019-11-25|2021-06-03|Regeneron Pharmaceuticals, Inc.|Crispr/cas-mediated upregulation of humanized ttr allele|
    WO2021195079A1|2020-03-23|2021-09-30|Regeneron Pharmaceuticals, Inc.|Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use|
    WO2021231661A2|2020-05-13|2021-11-18|Juno Therapeutics, Inc.|Process for producing donor-batched cells expressing a recombinant receptor|
    WO2021260186A1|2020-06-26|2021-12-30|Juno Therapeutics Gmbh|Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods|
    法律状态:
    2020-10-27| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-10-27| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
    2021-02-23| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2021-03-09| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US34328710P| true| 2010-04-26|2010-04-26|
    US61/343,287|2010-04-26|
    PCT/US2011/000725|WO2011139335A1|2010-04-26|2011-04-25|Genome editing of a rosa locus using zinc-finger nucleases|
    [返回顶部]